Results 141 to 150 of about 2,279,526 (315)

Science Education News, Fall 2025

open access: yes
Contents: --- A Message from the Director of Science Education, Lawrence Escalada--- Faculty Profile: Jesse Wilcox--- Staff Profile: Lori Wurtz--- Student Profile: Graduate student Caleb Christine--- Student Profile: Undergraduate student: Eliana Nava---
University of Northern Iowa. Science Education Program.
core  

Exploring the tension and synergies between science and technology in science education

open access: yes, 2009
This chapter explores the way in which technology has been introduced through and by science educators in Australasia in the last 25 years. A number of themes have arisen in this time from using technology to engage students in science, exploring the ...
Jones, Alister
core  

Stimulator of interferon genes agonist augmented antitumor immunity of osimertinib in Egfr‐mutated lung cancer

open access: yesMolecular Oncology, EarlyView.
Combining osimertinib with the STING agonist ADU‐S100 activates innate and adaptive immunity to overcome the non‐inflamed microenvironment of Egfr‐mutant lung cancer. This combination increases NK and CD8+ T‐cell infiltration, associated with activation of the STING‐IRF3 pathway and local immunogenic cell death.
Jun Nishimura   +19 more
wiley   +1 more source

Trends of science education research: An automatic content analysis

open access: yes, 2014
[[abstract]]This study used scientometric methods to conduct an automatic content analysis on the development trends of science education research from the published articles in the four journals of International Journal of Science Education, Journal of ...
Chang, Y. H.;Chang, C. Y.;Tseng, Y. H.
core  

Poetic science can enrich medical and science education

open access: yesFrontiers in Neurology, 2015
Sherry-Ann eBrown
doaj   +1 more source

Loss of IGF‐1R impairs DNA‐PKcs recruitment to chromatin leading to defective end‐joining

open access: yesMolecular Oncology, EarlyView.
IGF‐1R promotes radioresistance by facilitating DNA‐PKcs recruitment to chromatin, enabling non‐homologous end‐joining (NHEJ) repair of double‐strand breaks. Inhibition or loss of IGF‐1R disrupts this recruitment to damage sites, driving compensatory reliance on microhomology‐mediated end‐joining (MMEJ) repair.
Matthew O. Ellis   +3 more
wiley   +1 more source

Flow Enabled Target Capture Halbach‐based magnetic enrichment increases circulating tumor cell capture from blood in metastatic cancer patients

open access: yesMolecular Oncology, EarlyView.
Pair‐wise comparison of the CellSearch and FETCH enrichment technologies for circulating tumor cells (CTCs) from metastatic breast, prostate, and small cell lung cancer patients shows an increased capture of CTCs using FETCH enrichment. The clinical implementation of circulating tumor cells (CTCs) as a predictive tool for therapy efficacy in the ...
Michiel Stevens   +6 more
wiley   +1 more source

Science Education News, Fall 2024

open access: yes
Contents: --- A Message from the Director --- Faculty Profile: Kyle Gray --- MA Science Education --- Student Profiles: Emma Bopp, Wyatt Heideman, Jim Duff --- Yager Science Education Resources & Outreach --- Science Education Happenings --- 2024-2025 ...
University of Northern Iowa. Science Education Program.
core  

USP29‐regulated noncanonical stabilization of the hypoxia‐inducible factor‐α in aggressive prostate cancer

open access: yesMolecular Oncology, EarlyView.
We identify USP29 as the only DUB mirroring CA9 expression, a marker of hypoxia and HIF pathway activation associated with PCA aggressiveness. USP29 stabilizes HIF‐1α and HIF‐2α via a noncanonical mechanism that is independent of PHD/pVHL activity yet relies on proteasomal regulation, establishing USP29 as a previously unrecognized regulator of hypoxic
Amelie S Schober   +16 more
wiley   +1 more source

Longitudinal genome‐wide aneuploidy measurements in circulating cell‐free DNA to predict lack of benefit from pembrolizumab in patients with metastatic urothelial cancer

open access: yesMolecular Oncology, EarlyView.
Many patients with urothelial cancer do not benefit from treatment with pembrolizumab, while at risk of severe side effects. Changes in the levels of circulating tumor DNA early during treatment, measured by a simple and affordable assay that can be easily implemented in the clinic, can be used as a prognostic tool to identify these patients.
Youssra Salhi   +14 more
wiley   +1 more source

Home - About - Disclaimer - Privacy